PHARMACY

Study: Some African-American diabetics at risk of developing retinal disease

BY Alaric DeArment

NEW YORK African-American diabetics who consume large amounts of calories and sodium risk developing more severe retinal disease than those who don’t, according to a study published in the January issue of Archives of Ophthalmology.

Researchers at the New York University College of Dentistry and the New Jersey Medical School at the University of Medicine and Dentistry of New Jersey examined 469 African-American patients with Type 1 diabetes who enrolled in the study between 1993 and 1998, administering eye exams, blood tests and a diet questionnaire after a six-year follow-up.

Those with the highest caloric intake at the beginning of the study were more likely to develop retinopathy leading to vision loss by the end of the six-year period, while those with high sodium intake had the highest risk of developing macular edema.

“In African American patients with Type 1 diabetes, high caloric and sodium intakes are significant and independent risk factors for progression to severe forms of diabetic retinopathy,” the authors wrote. “These results suggest that low caloric and sodium intakes in African American individuals with Type 1 diabetes mellitus may have a beneficial effect on the progression of diabetic retinopathy and thus might be part of dietary recommendations for this population.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

New report projects sales of Parkinson’s disease drug will reach $500 million

BY Alaric DeArment

WALTHAM, Mass. A drug made by Boehringer Ingelheim for treating Parkinson’s disease could have sales of up to half a billion dollars, according to a new analysis.

According to a report released Tuesday by market research firm Decision Resources, BI’s extended-release formulation of pramipexole will have peak-year sales of between $250 million and $500 million in major pharmaceutical markets. The drug was launched in Europe in 2009 and is expected to enter the market in the United States this year.

In the beginning, according to the report, launches of generic formulations of the immediate-release version of pramipexole and competition from GlaxoSmithKline’s and SkyePharma’s Requip XL (ropinirole CR) and generic versions of immediate-release Requip will put a damper on sales of pramipexole ER. However, physician familiarity with the drug and preference among physicians and patients for once-daily dosing will cause a “significant” increase in sales.

“Given physician comfort in prescribing pramipexole for Parkinson’s disease and the convenience of once-daily dosing that it would offer, we expect that pramipexole ER will take much of pramipexole IR’s patient share,” Decision Resources analyst Sami Fam said. “In the short term, we expect pramipexole ER will lose some patient share to ropinirole CR given that ropinirole CR was the first of the two agents to launch. But over the long term, physicians’ slight preference for pramipexole over ropinirole should help to boost pramipexole ER’s uptake.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Report: Weis Markets acquires local Medicine Shoppe pharmacy

BY Michael Johnsen

SUNBURY, Pa. Weis recently acquired a Medicine Shoppe pharmacy in the Binghamton, N.Y., market, local newscaster News Channel 34 (owned by Newport Television) reported early Tuesday morning.

Weis Markets currently has 120 in-store pharmacies at other locations and is considering more at its Broome County locations, the report noted.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES